 In this study, researchers found that decreased levels of FASN protein in the lungs of people with idiopathic pulmonary fibrosis, IPF, and mice treated with gliomycin, BLM, were linked to mitochondrial dysfunction and increased oxidative stress. They also discovered that increasing FASN levels could reduce BLM-induced lung damage and inflammation. This suggests that FASN may play a critical role in the development of IPF and could potentially be used as a target for new treatments. This article was authored by Haishan Shin, Shinhee Park, Jisoo Hong, and others.